Sponsor Pipeline

Nanjing IASO Biotechnology Co., Ltd. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
10
Active Trials
5
Recruiting
1
Phase 3
4
Disease Areas
What Changed in the Last 30 Days
First PostedNew Trial FilingPhaseStatus
2026-08-07 NCT07752264 A Phase I/II Study of Eque-cel in Subjects Withimmune-mediated Necrotizing Myopathy Phase 1/2 Not Yet Recruiting
Active Trials by Phase
Phase 3
1
Phase 2
1
Phase 1/2
3
Phase 1
4
Not specified
1
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT06464991 A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03) Multiple Myeloma Recruiting
Phase 2
NCT07055724 Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis AL Amyloidosis Not Yet Recruiting
Phase 1/2
NCT05091541 A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's… B-cell Non-Hodgkin's Lymphoma Not Yet Recruiting
NCT07510100 Eque-cel for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma Relapsed/Refractory Multiple Myeloma Not Yet Recruiting
NCT07752264 A Phase I/II Study of Eque-cel in Subjects Withimmune-mediated Necrotizing Myopathy Refractory Immune-mediated Necrotizing Myopathy Not Yet Recruiting
Phase 1
NCT05759793 A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma… Relapsed/Refractory Multiple Myeloma Recruiting
NCT06743503 UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies Large B-cell Lymphoma Recruiting
NCT07109986 UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus… Systemic Lupus Erythematosus Recruiting
NCT05181501 A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk… Multiple Myeloma Not Yet Recruiting
Not specified
NCT07028970 Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection Multiple Myeloma Recruiting
Disease Areas
Get alerts when Nanjing IASO Biotechnology Co., Ltd.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free